Literature DB >> 22067386

The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44.

Vittorio Perfetti1, Giovanni Palladini, Simona Casarini, Valentina Navazza, Paola Rognoni, Laura Obici, Rosangela Invernizzi, Stefano Perlini, Catherine Klersy, Giampaolo Merlini.   

Abstract

Monoclonal Ig light chains (LC) can be responsible for pathologic conditions in humans, as in systemic amyloid light amyloidosis. Protean clinical manifestations characterize this disorder with the most varied combination of symptoms generated by different degrees of diverse organ involvement. Kidney and heart are most frequently interested, with major heart involvement as the most relevant prognostic factor. The identification of the underlying mechanism involved in organ targeting is of major relevance for the pathobiology of this disorder. To this aim, we characterized the repertoire of variable region germline genes of λ LC preferentially targeting the heart and compared it with the repertoire of LC that do not in a case-control study. We found that the repertoires were highly restricted, showing preferential use of the same few germline genes but with a different frequency pattern. A single gene, IGVL1-44, was found associated with a 5-fold increase in the odds of dominant heart involvement (after adjusting for confounders in a multivariable logistic model). These results support an involvement of LC genetics in the determination of organ targeting. Study of the characteristics of IGVL1-44-LC with, and of the minority without, heart involvement might lead to identification of LC/tissue interactions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22067386     DOI: 10.1182/blood-2011-05-355784

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  Congestive heart failure: a case of protein misfolding.

Authors:  Chung-Eun Ha; Nadhipuram V Bhagavan; Miki Loscalzo; Stephen K Chan; Huy V Nguyen; Carlos N Rios; Stacey A A Honda
Journal:  Hawaii J Med Public Health       Date:  2014-06

2.  Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis.

Authors:  Brendan M Weiss; Joseph Hebreo; Daniel V Cordaro; Mark J Roschewski; Thomas P Baker; Kevin C Abbott; Stephen W Olson
Journal:  J Clin Oncol       Date:  2014-07-14       Impact factor: 44.544

3.  Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.

Authors:  Yujia Wang; Lushuang Xu; Yang Liu; Yuzhe Hu; Qiang Shi; Lixue Jin; Lijun Yang; Pingzhang Wang; Kunshan Zhang; Xiaojun Huang; Qing Ge; Jin Lu
Journal:  Int J Hematol       Date:  2020-10-10       Impact factor: 2.490

Review 4.  New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.

Authors:  Stefano Perlini; Roberta Mussinelli; Francesco Salinaro
Journal:  Curr Heart Fail Rep       Date:  2016-12

5.  Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome.

Authors:  Sébastien Bender; Vincent Javaugue; Alexis Saintamand; Maria Victoria Ayala; Mehdi Alizadeh; Matthieu Filloux; Virginie Pascal; Nathalie Gachard; David Lavergne; Fabienne Auroy; Michel Cogné; Frank Bridoux; Christophe Sirac; Arnaud Jaccard
Journal:  Blood       Date:  2020-05-14       Impact factor: 22.113

Review 6.  AL amyloidosis: from molecular mechanisms to targeted therapies.

Authors:  Giampaolo Merlini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.

Authors:  Sohsuke Meshitsuka; Sumito Shingaki; Masatoshi Hotta; Miku Goto; Makoto Kobayashi; Yuuichi Ukawa; Yuko M Sagesaka; Yasuyo Wada; Masanori Nojima; Kenshi Suzuki
Journal:  Int J Hematol       Date:  2016-11-04       Impact factor: 2.490

Review 8.  Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Perry Elliott; Raymond Comenzo; Marc Semigran; Claudio Rapezzi
Journal:  Circulation       Date:  2017-04-04       Impact factor: 29.690

Review 9.  Amyloid formation in light chain amyloidosis.

Authors:  Marina Ramirez-Alvarado
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

Review 10.  Animal models of monoclonal immunoglobulin-related renal diseases.

Authors:  Christophe Sirac; Guillermo A Herrera; Paul W Sanders; Vecihi Batuman; Sebastien Bender; Maria V Ayala; Vincent Javaugue; Jiamin Teng; Elba A Turbat-Herrera; Michel Cogné; Guy Touchard; Nelson Leung; Frank Bridoux
Journal:  Nat Rev Nephrol       Date:  2018-02-19       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.